

# Market Announcement

28 November 2023

---

## BOD Science Limited (ASX: BOD) – Suspension from Quotation

### Description

The securities of BOD Science Limited ('BOD') will be suspended from quotation immediately under Listing Rule 17.2, at the request of BOD, pending the release of an announcement regarding a potential corporate transaction critical to its continued financial viability.

### Issued by

**Lisa Banh**

Senior Adviser, Listings Compliance



28 November 2023

ASX Compliance Pty Ltd  
20 Bridge Street  
Sydney NSW 2000

By email: [tradinghaltssydney@asx.com.au](mailto:tradinghaltssydney@asx.com.au)

**Bod Science Limited (ASX: BOD)  
Request for Voluntary Suspension**

Bod Science Limited ACN 601 225 441 (the **Company** or **Bod**) refers to the trading halt granted by ASX on 24 November 2023.

Pursuant to Listing Rule 17.2, the Company requests a voluntary suspension of trading in its securities from the commencement of trading today, 28 November 2023.

In accordance with Listing Rule 17.2, the Company advises that:

1. The voluntary suspension is requested pending an announcement to be released to the ASX by the Company regarding an alternative corporate transaction that is critical to the Company's financial viability.
2. The Company expects the voluntary suspension to last for no longer than three trading days.
3. The Company requests that the voluntary suspension remain in place until the earlier of such time as it makes an announcement to the market and the commencement of trading on Friday, 1 December 2023.
4. The Company is not aware of any reason why its securities should not be suspended, or of any other information available at this stage that is relevant to the voluntary suspension.

**Authorised for release by the Chair of Bod Science Limited.**

**ENDS**

**About Bod Science**

Bod Science (ASX:BOD) is a cannabis focused drug development and product innovation company.

Bod is focused on progressing research and development with a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for patients and consumers. The Company has a number of existing partnerships with large corporate companies and collaborations with leading research organisations to advance the use of Cannabis related medicines with therapeutic indications.

**For more information please contact:**

Jo Patterson  
Chief Executive Officer  
[Info@bodaustralia.com](mailto:Info@bodaustralia.com)  
+61 2 9199 5018